Chemesis International Inc. Enters into Binding Agreement to Acquire 100% of an Arizona based Manufacturing Facility
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. Enters into Binding Agreement to Acquire 100% of an Arizona
based Manufacturing Facility
Chemesis has Entered into a Binding agreement to Acquire a Fully Operational Facility in Arizona which is in
the process of GMP Certification
April 15, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), announces it has entered into a Binding agreement to acquire a fully operational cannabis
manufacturing facility in Arizona (“Facility”), establishing the Company as a Multi-State Operator. During
its operations in calendar Q1 2019, the Facility earned revenues of approximately USD $1,000,000.
The Facility is 5,000 square feet and is a turn key solution that comes with a team of operators in place.
The Facility currently produces finished goods products, such as hard and soft -capsules, cartridges,
lotions, tinctures, and other liquid formulations. Additionally, the Facility focuses on producing products
that are 100% Cannabidiol (CBD).
The Company has continued to focus on its ability to enter the CBD market by adding manufacturing
capabilities in California and now in Arizona. The CBD market potential across the United States
continues to grow and Chemesis is positioning itself to quickly gain market share in an industry that is
expected to exceed $2.1 billion by 2020 1. The Facility will leverage the 2018 U.S. Farm Bill to further
capitalize on the expected increased demand for CBD.
“The Facility in Arizona gives Chemesis a turn key solution that brings strong bottom line revenues and a
team of operators that will help the Company expand its multi -state operations,” said CEO of Chemesis,
Edgar Montero. “Chemesis plans to explore expansion opportunities into additional sta tes as the
cannabis industry continues to see further validation. The acquisition brings a team of individuals that
brings a wealth of experience that we believe will allow Chemesis to gain market share.”
Under the terms of this acquisition, Chemesis will issue 250,000 shares at a deemed price of CDN $2.11.
The Company expects to close its previously announced acquisition of the California fully licensed
cannabis extraction and manufacturing facility within the next ten days.
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
1 Hemp Business Journal
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently
operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution
and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective
production and distribution of its products. In ad dition, Chemesis leverages exclusive brands and
partnerships and uses the highest quality extraction methods to provide consumers with quality
cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while con sistently
delivering quality product to its consumers from seed to sale.
Investor Relations:
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "fo rward-looking information" within the meaning of
applicable securities laws, including in relation to statements regarding the Acquisition, the anticipated benefits of
the Acquisition, the expected size of the CBD market, the Company’s ability to increase production of various
cannabidiol products, and generally regarding the business, products and future of the Company’s business, its
product offerings and plans for sales and marketing, including upon completion of the Acquisition. Although the
Company believes that the expectations reflected in the forward -looking information are reasonable, there can be
no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on
forward-looking information. Such forw ard-looking statements are subject to risks and uncertainties that may
cause actual results, performance and developments to differ materially from those contemplated by these
statements depending on, among other things, the risks that the Acquisition will not be completed as proposed or
at all, that the anticipated benefits of the Acquisition will not materialize, that the CDB market will not expand as
anticipated, that the Company will not be able to expand production of CDB products at the rate anticipat ed upon
closing of the Acquisition (or at all), and generally that the Company's products and plan will vary from those stated
in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation and does not intend to update any forward -
looking statements or forward -looking information in this news release. Although the Company believes that the
expectations reflected in the forward -looking information ar e reasonable, there can be no assurance that such
expectations will prove to be correct and makes no reference to profitability based on sales reported. The
statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release